Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Rybrevant
Pharma
J&J's Rybrevant-Lazcluze tops AZ's Tagrisso on overall survival
J&J’s combo of Rybrevant and Lazcluze has racked up an overall survival win versus AZ’s Tagrisso in first-line non-small cell lung cancer.
Kevin Dunleavy
Jan 7, 2025 8:00am
J&J, AZ approval filings rejected by FDA
Dec 17, 2024 10:02am
EU regulators endorse meds from BMS, J&J, Eisai and more
Nov 15, 2024 10:05am
FDA expands label for AZ's Tagrisso in NSCLC indication
Sep 26, 2024 10:52am
J&J earns 3rd NSCLC nod in 7 months for surging Rybrevant
Sep 20, 2024 11:00am
J&J builds case for Tagrisso rival with survival analysis
Sep 8, 2024 2:07pm